Antimetabolic cooperativity with the clinically approved l-asparaginase and tyrosine kinase inhibitors to eradicate CML stem cells

OBJECTIVE: Long-term treatment with tyrosine kinase inhibitors (TKI) represents an effective cure for chronic myeloid leukemia (CML) patients and discontinuation of TKI therapy is now proposed to patient with deep molecular responses. However, evidence demonstrating that TKI are unable to fully erad...

Descripción completa

Detalles Bibliográficos
Autores principales: Trinh, Anne, Khamari, Raeeka, Fovez, Quentin, Mahon, François-Xavier, Turcq, Béatrice, Bouscary, Didier, Maboudou, Patrice, Joncquel, Marie, Coiteux, Valérie, Germain, Nicolas, Laine, William, Dekiouk, Salim, Jean-Pierre, Sandrine, Maguer-Satta, Veronique, Ghesquiere, Bart, Idziorek, Thierry, Quesnel, Bruno, Kluza, Jerome, Marchetti, Philippe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8732793/
https://www.ncbi.nlm.nih.gov/pubmed/34863941
http://dx.doi.org/10.1016/j.molmet.2021.101410

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8732793/
https://www.ncbi.nlm.nih.gov/pubmed/34863941
http://dx.doi.org/10.1016/j.molmet.2021.101410

Ejemplares similares